Savara Inc. faces a lawsuit for allegedly hiding flaws in its drug application, leading to a 31.7% stock drop after the FDA rejected it.

A securities class action lawsuit has been filed against Savara Inc. (SVRA) alleging that the company misled investors from March 7, 2024, to May 23, 2025, by failing to disclose critical flaws in its MOLBREEVI drug’s Biologics License Application, including insufficient chemistry, manufacturing, and controls data. The FDA issued a refusal-to-file letter on May 27, 2025, citing incompleteness, causing Savara’s stock to drop 31.69% to $1.94. Investors who lost money during the class period may apply to lead the lawsuit by November 7, 2025. The case is pending, and no outcome is guaranteed.